Human Reproductive Technologies: Products and Global Markets
The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.
- An overview of the market for human reproductive technologies.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examinations of market sizes in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception, and sexual dysfunction, with a division of markets according to treatment type and indication.
- Evaluations of pipeline products and technologies.
- Patent analysis.
SCOPE OF STUDY
The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.
- Infertility market—male and female factors, pharmaceuticals and future advancements.
- Assistive reproductive technologies.
- Fertility diagnostics.
- Contraception—pharmaceuticals and devices.
- Sexual dysfunction—pharmaceuticals and devices.
Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013.
Frequently Asked Questions (FAQs)
Mary Anne Crandall is a medical research analyst and has specialized in the pharmaceuticals and medical device industry for the last 25 years. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry. She is a retired nurse, has a B.S. and an M.S. in Psychology and is currently working on her Ph.D.
The total U.S. market for reproductive technologies and products is estimated to be $6.5 billion in 2004. In 2009, revenues will likely reach $9.8 billion, rising at an average annual growth rate (AAGR) of 8.6%.
Contraceptive products currently account for the highest amount of revenues and are expected to grow at an AAGR of 9.1% through the period.
Sexual dysfunction products are expected to show the highest annual growth at an average of 12.3% through 2009.
Few areas in medicine have posed so many social and ethical questions and attracted so much public attention as has assisted reproductive technology (ART) to manage infertility.
The total U.S. market for human reproductive technologies reached $6.9 billion in 2001. It is expected to rise at an AAGR (average annual growth rate) of 10.1% to $11 billion in 2006.
Treatments for infertility will show the most dynamic growth during the forecast period among reproductive technology products. The market for infertility treatments, both pharmaceuticals and procedures, is expected to exhibit an average annual growth rate (AAGR) of 19.7% from 2001 to 2006. Approximately 28% of the market in 2001 was generated by fertility drugs and the remainder of the market was contributed by revenues from assisted reproductive technologies (ARTs), primarily in vitro fertilization (IVF).